A one-year study from Northwest China reports that ultrasound cycloplasty reduced intraocular pressure by nearly 60 percent, halved dangerous 24-hour pressure fluctuations, and produced no severe ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, ...

Eye care providers urged FDA advisers to approve SYD-101, citing myopia’s lifelong risks, compounding gaps and STAR trial ...

A 25-year-old Black man presented to the Tufts Medical Center emergency department with blurred vision in both eyes.The ...

A new review finds that while AREDS formulations remain the only well-established nutritional therapy for retinal disease, ...

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September ...

Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with diabetic macular edema (DME) Remigromig is the ...

Discover five myopia companies racing to go beyond glasses, as myopia is set to affect half the world by 2050.

With two highly differentiated branded prescription products, Harrow believes it can give eyecare professionals greater flexibility to individualize treatment based on their patients' needs and ...

License agreement also grants Glaukos exclusive rights to the RevMod™ platform for the discovery and development of up to four additional next-generation biologics for various retinal diseases ALISO ...

Auckland Eye hosted an event debunking common eyecare myths, covering topics like carrots and night vision, nAMD injections, vitrectomy ...